Premium
Meta AMSA (m‐AMSA) in Patients with Advanced Ovarian Carcinoma
Author(s) -
Kearsley John H.,
Page Jonathon P.,
Levi John A.,
Woods Robert L.,
Tattersall Martin H. N.,
Fox Richard M.,
Coates Alan S.
Publication year - 1982
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.1982.tb01416.x
Subject(s) - medicine , ovarian cancer , ovarian carcinoma , toxicity , oncology , cancer
Summary: A phase 2 study of 4 1 ‐(9‐acridinylamino) methane‐sulfon‐m‐anisidide (meta‐AMSA) was conducted in previously treated patients with advanced ovarian cancer. Two of 14 patients (14%) evaluable for tumour response achieved partial remissions for 9 and 18 weeks and 8 of the 14 (57%) maintained stable disease for periods ranging from 3 to 24 weeks. Myelosuppression, particularly leucopenia, proved the major toxicity, occurring in 45% of treatment courses. Meta‐AMSA has only modest antitumour efficacy as a single agent in the treatment of advanced ovarian cancer.